American Century Companies Inc. Purchases 95,777 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

American Century Companies Inc. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,140,705 shares of the specialty pharmaceutical company's stock after purchasing an additional 95,777 shares during the period. American Century Companies Inc. owned approximately 2.07% of Supernus Pharmaceuticals worth $41,248,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Smartleaf Asset Management LLC grew its position in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth about $72,000. Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $92,000. KBC Group NV grew its holdings in shares of Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock valued at $97,000 after purchasing an additional 929 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $211,000.

Analysts Set New Price Targets

SUPN has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday.

Remove Ads

Supernus Pharmaceuticals Trading Down 3.3 %

NASDAQ:SUPN traded down $1.07 during mid-day trading on Tuesday, hitting $31.68. 608,392 shares of the company's stock were exchanged, compared to its average volume of 479,334. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The firm has a market capitalization of $1.77 billion, a P/E ratio of 29.61 and a beta of 0.83. The company has a 50 day simple moving average of $34.91 and a 200-day simple moving average of $35.06.

Insider Activity

In related news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,104 shares of company stock valued at $440,263. Insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.